Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study

Andrew X. Zhu; Jennifer J. Knox; Masatoshi Kudo; Stephen L. Chan; Richard S. Finn; A.B. Siegel; J. Ma; P.A. Watson; Ann‐Lii Cheng

doi:10.1093/annonc/mdw371.108

Related publications

Article2017

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

Andrew X. Zhu, Jennifer J. Knox, Masatoshi Kudo, Stephen L. Chan, Richard S. Finn, Abby B. Siegel, Junshui Ma, P.A. Watson, Ann‐Lii Cheng

Article2018

KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Andrew X. Zhu, Richard S. Finn, Stéphane Cattan, Julien Edeline, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Olivier Rosmorduc, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo

Article2021

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.

Jean‐Luc Van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Michael Chisamore, Anran Wang, Andrew X. Zhu

Article2018

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar,

Article2022

SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

Peter Vogel, Julien Edeline, Sadahisa Ogasawara, Masatoshi Kudo, R. Finn, D. Palmer, Chris Verslype, Vittorina Zagonel, L. Fartoux, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Aristine Cheng, B. Daniele, T. Yau, A. Wang, Ken Hatogai, A.B. Siegel, S. Cattan